Literature DB >> 12969373

Binding and entry of respiratory syncytial virus into host cells and initiation of the innate immune response.

James Harris1, Dirk Werling.   

Abstract

Respiratory syncytial virus (RSV) is the most common cause of severe lower respiratory tract infection in infants and the elderly. There is currently no effective antiviral treatment for the infection, but advances in our understanding of RSV uptake, especially the role of surfactant proteins, the attachment protein G and the fusion protein F, as well as the post-binding events, have revealed potential targets for new therapies and vaccine development. RSV infection triggers an intense inflammatory response, mediated initially by the infected airway epithelial cells and antigen-presenting cells. Humoral and cell-mediated immune responses are important in controlling the extent of infection and promoting viral clearance. The initial innate immune response may play a critical role by influencing the subsequent adaptive response generated. This review summarizes our current understanding of RSV binding and uptake in mammalian cells and how these initial interactions influence the subsequent innate immune response generated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12969373     DOI: 10.1046/j.1462-5822.2003.00313.x

Source DB:  PubMed          Journal:  Cell Microbiol        ISSN: 1462-5814            Impact factor:   3.715


  22 in total

1.  Effects of alveolar macrophage depletion on liposomal vaccine protection against respiratory syncytial virus (RSV).

Authors:  A Benoit; Y Huang; J Proctor; G Rowden; R Anderson
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

2.  Role of EXT1 and Glycosaminoglycans in the Early Stage of Filovirus Entry.

Authors:  Aileen O'Hearn; Minxiu Wang; Han Cheng; Calli M Lear-Rooney; Katie Koning; Emily Rumschlag-Booms; Elizabeth Varhegyi; Gene Olinger; Lijun Rong
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

3.  Identification of linear heparin-binding peptides derived from human respiratory syncytial virus fusion glycoprotein that inhibit infectivity.

Authors:  Roberta L Crim; Susette A Audet; Steven A Feldman; Howard S Mostowski; Judy A Beeler
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

4.  Conserved glycine residues in the fusion peptide of the paramyxovirus fusion protein regulate activation of the native state.

Authors:  Charles J Russell; Theodore S Jardetzky; Robert A Lamb
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

5.  Anti-inflammatory effect of MUC1 during respiratory syncytial virus infection of lung epithelial cells in vitro.

Authors:  Yusheng Li; Darrell L Dinwiddie; Kevin S Harrod; Yong Jiang; K Chul Kim
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-01-15       Impact factor: 5.464

Review 6.  Human genetic factors and respiratory syncytial virus disease severity.

Authors:  Isao Miyairi; John P DeVincenzo
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

7.  Respiratory syncytial virus infection reduces lung inflammation and fibrosis in mice exposed to vanadium pentoxide.

Authors:  Elizabeth A Turpin; Aurita Antao-Menezes; Mark F Cesta; James B Mangum; Duncan G Wallace; Edilberto Bermudez; James C Bonner
Journal:  Respir Res       Date:  2010-02-22

8.  p38 and OGT sequestration into viral inclusion bodies in cells infected with human respiratory syncytial virus suppresses MK2 activities and stress granule assembly.

Authors:  Jens Fricke; Lily Y Koo; Charles R Brown; Peter L Collins
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

Review 9.  Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma.

Authors:  Shyam S Mohapatra; Sandhya Boyapalle
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

10.  Role of licochalcone A on thymic stromal lymphopoietin expression: implications for asthma.

Authors:  Sung-Ho Kim; Min Yang; Jian-Gang Xu; Xi Yu; Xue-Jiao Qian
Journal:  Exp Biol Med (Maywood)       Date:  2014-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.